Abzena runs head-to-head comparative studies across conjugation chemistry, release mechanism, and OAR early in development.
Published
Signal category
Products & Services
Quote
“Abzena runs head-to-head comparative studies across conjugation chemistry, release mechanism, and OAR early in development”
— Abzena team
Company
Abzena
Abzena is the leading integrated bioconjugate & complex biologics CDMO+CRO, focused on rapidly moving medicines forward.
- Industry
- Pharmaceutical Manufacturing
- Location
- San Diego, US
- Company size
- 446 employees
Abzena is the leading end-to-end bioconjugate, ADC, and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule and move medicines forward faster. The company has research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK.
Founded 2001